Exhibit 99.1
ABIOMED ANNOUNCES FOURTH QUARTER GAAP EPS OF $0.09 ON RECORD REVENUE AND PATIENTS SUPPORTED
Full Year Revenue Exceeds Management Guidance
DANVERS, Mass., May 2, 2013 – Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2013 revenue of $43.7 million, up 17% compared to revenue of $37.3 million in the same period of fiscal 2012, and fourth quarter fiscal 2013 GAAP net income of $3.7 million or $0.09 per diluted share, compared to GAAP net income of $2.6 million or $0.06 per diluted share in the prior year. For the full fiscal year 2013, total revenue was $158.1 million, up 25% compared to $126.4 million for fiscal year 2012, and GAAP net income was $15.0 million or $0.37 per share, compared to GAAP net income of $1.5 million or $0.04 per diluted share in the prior year.
Financial and operating highlights during the fourth quarter of fiscal 2013 include the following:
| • | As previously announced on April 17, 2013, fiscal fourth quarter worldwide Impella® revenue totaled $39.3 million, up 22% compared to revenue of $32.3 million during the same period of the prior year. Full year worldwide Impella revenue totaled $140.3 million, up 31% compared to $106.9 million for fiscal year 2012. |
| • | Fiscal fourth quarter U.S. Impella revenue grew 22% to $36.5 million from $29.9 million in the prior year. Full year U.S. Impella revenue grew 32% to $131.3 million from $99.1 million in the prior year. |
| • | An additional 30 hospitals purchased Impella 2.5 during the quarter, bringing the total to 748 U.S. Impella customer sites. As part of Abiomed’s continued controlled Impella CP launch, an additional 55 hospitals purchased Impella CP™, bringing the total number of Impella CP U.S. sites to 106. |
| • | Gross margin rate for the fourth quarter fiscal 2013 was 79.8% compared to 81.8% in the prior year. For the full fiscal year, gross margin rate was 80.0% compared to 80.6% in the prior year. |
| • | Operating margin rate for the fourth quarter fiscal 2013 was 9.5%, compared to 7.9% in the prior year period. For the full fiscal year, operating margin rate was 10.4% compared to 1.2% in the prior year. |
| • | Cash, cash equivalents, short and long-term marketable securities totaled $88.1 million as of March 31, 2013, an increase of $2.4 million from December 31, 2012. The Company continues to have no debt and a U.S.federal net operating loss carry-forward of approximately $190 million as of March 31, 2012. |
| • | Abiomed announced in February that it received a close-out letter from the Food and Drug Administration (FDA) Office of Compliance with respect to its previous FDA warning letter dated June 10, 2011. The close-out letter stated that the FDA Office of Compliance has completed its evaluation of the corrective actions taken by Abiomed in response to the previously disclosed FDA warning letter and that the concerns cited in that letter appear to have been addressed. |
| • | In February, an economic study on the use of percutaneous ventricular assist devices (pVAD) was published in the February edition of The Journal of Managed Care Medicine (JMCM), “A Budget Impact Model to Estimate the Cost Dynamics of Treating High-Risk Heart Failure Patients with Advanced Percutaneous Cardiac Assist Devices: The Payer Perspective.” Additionally, in May, the PROTECT II cost-effective study was published in the American Health and Drug Benefits Journal. |
| • | Abiomed also announced several reimbursement milestones in March, including recent Impella coverage decisions from national payers including Humana, UnitedHealthcare, Independence Blue Cross and Capital BlueCross. The recently updated coverage decisions include new Impella policies in the payers’ commercial and/or Medicare Advantage plans. |
| • | In April, Abiomed also announced the enrollment of the first patient in RECOVER RIGHT, an Investigational Device Exemption (IDE) study of Impella® RP (Right Peripheral). The Impella RP is a percutaneous heart pump that is implanted through a single access site in the patient’s leg and deployed through the venous system, across the right side of the heart without requiring a surgical procedure. The RECOVER RIGHT clinical study, which received FDA IDE approval to begin in November 2012, will enroll 30 patients that present with signs of right side heart failure and are being treated in the catheterization lab or cardiac surgery suite. |
“We are proud to report another record quarter and record fiscal year in both number of patients supported and total revenue,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. “Our company has transformed into a resilient commercial organization, that is profitable, debt free and expanding the number of exclusive regulatory approvals, breakthrough innovative products and geographical reach.”
Based on current expectations, Abiomed expects fiscal year 2014 revenue to be in the range of $180 million to $185 million. Worldwide Impella revenue is forecasted to increase by approximately 20%. GAAP operating margin rate for the full fiscal year is expected to be in the range of 7% to 8% of revenue, including estimated legal costs of approximately $6.0 million to $8.0 million associated with the Department of Justice and shareholder matters.
The Company will host a conference call to discuss the fourth quarter and full fiscal year 2013 results today at 8:00 a.m. ET with Michael R. Minogue, Chairman, President and Chief Executive Officer; Robert L. Bowen, Vice President and Chief Financial Officer; and Susan V. Lisa, Senior Director of Investor Relations and Corporate Development.
To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (877) 638-9567; the international number is (253) 237-1032. A replay of this conference call will be available beginning at 11 a.m. ET May 2, 2013 through 11:59 p.m. ET on May 10, 2013. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 36674557.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding development of Abiomed’s existing and new products, the Company’s progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
For further information please contact:
Susie Lisa, CFA
Senior Director, Investor Relations and Corporate Development
978-646-1590
slisa@abiomed.com
Aimee Genzler
Corporate Communications Manager
978-646-1553
ir@abiomed.com
###
Abiomed, Inc. and Subsidiaries
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share data)
| March 31, | ||||||||
| 2013 | 2012 | |||||||
| ASSETS |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 9,451 | $ | 5,990 | ||||
| Short-term marketable securities |
67,256 | 71,233 | ||||||
| Accounts receivable, net |
22,946 | 20,458 | ||||||
| Inventories |
14,930 | 11,142 | ||||||
| Prepaid expenses and other current assets |
2,022 | 1,716 | ||||||
|
|
|
|
|
|||||
| Total current assets |
116,605 | 110,539 | ||||||
| Long-term marketable securities |
11,406 | — | ||||||
| Property and equipment, net |
6,549 | 6,378 | ||||||
| Intangible assets, net |
— | 115 | ||||||
| Goodwill |
35,410 | 36,846 | ||||||
| Other long-term assets |
29 | 33 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 169,999 | $ | 153,911 | ||||
|
|
|
|
|
|||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 7,696 | $ | 6,910 | ||||
| Accrued expenses |
15,162 | 12,480 | ||||||
| Deferred revenue |
4,198 | 3,025 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
27,056 | 22,415 | ||||||
| Long-term deferred tax liability |
5,555 | 4,799 | ||||||
| Other long-term liabilities |
308 | 400 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
32,919 | 27,614 | ||||||
|
|
|
|
|
|||||
| Commitments and contingencies |
||||||||
| Stockholders’ equity: |
||||||||
| Class B Preferred Stock, $.01 par value |
— | — | ||||||
| Authorized - 1,000,000 shares; Issued and outstanding - none |
||||||||
| Common stock, $.01 par value |
397 | 393 | ||||||
| Authorized - 100,000,000 shares; Issued - 39,788,383 shares at March 31, 2013 and 39,323,708 shares at March 31, 2012; |
||||||||
| Outstanding - 38,601,384 shares at March 31, 2013 and 39,272,754 shares at March 31, 2012 |
||||||||
| Additional paid in capital |
414,810 | 401,771 | ||||||
| Accumulated deficit |
(258,261 | ) | (273,275 | ) | ||||
| Treasury stock at cost - 1,186,999 shares at March 31, 2013 and 50,954 shares at March 31, 2012 |
(16,129 | ) | (827 | ) | ||||
| Accumulated other comprehensive loss |
(3,737 | ) | (1,765 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
137,080 | 126,297 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 169,999 | $ | 153,911 | ||||
|
|
|
|
|
|||||
Abiomed, Inc. and Subsidiaries
Consolidated Statements of Operations
(Unaudited)
(in thousands, except share data)
| Three Months Ended March 31, |
Year
Ended March 31, |
|||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| Revenue: |
||||||||||||||||
| Product revenue |
$ | 43,536 | $ | 37,237 | $ | 157,614 | $ | 125,286 | ||||||||
| Funded research and development |
138 | 107 | 510 | 1,089 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| 43,674 | 37,344 | 158,124 | 126,375 | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Costs and expenses: |
||||||||||||||||
| Cost of product revenue |
8,826 | 6,786 | 31,596 | 24,507 | ||||||||||||
| Research and development |
6,822 | 7,236 | 25,647 | 27,159 | ||||||||||||
| Selling, general and administrative |
23,894 | 20,028 | 84,227 | 71,711 | ||||||||||||
| Amortization of intangible assets |
— | 352 | 111 | 1,478 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| 39,542 | 34,402 | 141,581 | 124,855 | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income from operations |
4,132 | 2,942 | 16,543 | 1,520 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Other income (expense): |
||||||||||||||||
| Investment (expense) income, net |
(7 | ) | 1 | (7 | ) | (3 | ) | |||||||||
| Gain on settlement of investment |
— | — | — | 1,017 | ||||||||||||
| Other income (expense), net |
15 | (15 | ) | 326 | 9 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| 8 | (14 | ) | 319 | 1,023 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income before provision for income taxes |
4,140 | 2,928 | 16,862 | 2,543 | ||||||||||||
| Income tax provision |
398 | 361 | 1,848 | 1,048 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income |
$ | 3,742 | $ | 2,567 | $ | 15,014 | $ | 1,495 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Basic net income per share |
$ | 0.10 | $ | 0.07 | $ | 0.38 | $ | 0.04 | ||||||||
| Basic weighted average shares outstanding |
38,445 | 38,840 | 39,113 | 37,159 | ||||||||||||
| Diluted net income per share |
$ | 0.09 | $ | 0.06 | $ | 0.37 | $ | 0.04 | ||||||||
| Diluted weighted average shares outstanding |
39,824 | 41,251 | 41,052 | 40,172 | ||||||||||||